Sun Pharmaceutical Industries Ltd. has announced entering into a license and supply agreement with Italy’s Cassiopea S.p.A. that will give the Indian company rights to market Winlevi (clascoterone) 1% cream in the US and Canada. The companies expect to make Winlevi available in the US in the fourth quarter of 2021.
Sun Strikes Deal For Clascoterone In US And Canada
Enters Into License And Supply Agreement With Italy’s Cassiopea For Winlevi
Sun Pharma has expanded its dermatology portfolio by entering into a partnership with Italy’ Cassiopea to market Winlevi (clascoterone) 1% cream in the US and Canada, and expects to make it available in the US inthe fourth quarter of 2021.
